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Jefferson Pancreas Tumor Registry Opens for Enrollment
The Jefferson Pancreas Tumor Registry (JeffPTR) has been approved by the Institutional Review Board of
Thomas Jefferson University Hospital and is designed to help determine the links between familial
genetic variations, environmental and occupational influences, and the development of pancreatic cancer.

According to Principal Investigator, Dr. Charles J. Yeo, "The purpose of the Jeff PTR is to determine
whether pancreas cancer occurs more frequently in families with a history of the disease, and to
determine the environmental and occupational risk factors to which pancreas cancer patients have been
exposed." Participants will complete a detailed questionnaire and may be asked to submit a blood sample
and/or cheek swab. The questionnaire is designed to elicit the family health history of a patient with
pancreas cancer or a non-affected family member, and to document exposure to occupational and
environmental factors, such as residential radon, asbestos, and second-hand tobacco smoke. The Jeff
PTR is a longitudinal study in which participants may engage in long-term follow-up and receive
information regarding scientific and epidemiological breakthroughs in pancreas cancer.
Research has shown that certain rare genetic conditions are associated with an increased risk of
pancreatic cancer, including familial breast-ovarian cancer, familial melanoma, familial colon cancer,
hereditary pancreatitis, and Peutz-Jegher's syndrome. Genetic Counselor Sarah Charles, MS, CGC of the
Jefferson Kimmel Cancer Center Network (JKCCN) educates families about their risk of developing an
inherited disorder. Ms. Charles explains, "We haven't yet identified a causative gene to allow predictive
testing for pancreatic cancer. But, for patients with a strong family history of pancreatic cancer, we can
offer risk assessments and possibly surveillance with endoscopic ultrasound."
Such high risk patients may be referred to Jefferson gastroenterologists such as Thomas Kowalski, MD
and David Loren, MD to discuss the pros and cons of invasive surveillance. The goal is to diagnose
pancreatic cancer early when it is easier to treat. For persons who do develop pancreatic cancer,
Jefferson physicians may use the results of genetic testing to select the most effective therapy. Targeted
therapy for pancreas cancer is becoming a reality in part due to recent discoveries made in the laboratory

of Jonathan Brody, PhD, Assistant Professor of Surgery, where molecular studies have clearly indicated
survival advantages with the use of targeted chemotherapy treatment.
For more information about the Jefferson Pancreas Tumor Registry please visit
www.jeffersonhospital.org/pancreasregistry.
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Clinical Integration

Overview

Charles J. Yeo, MD
Samuel D. Gross Professor and
Chair, Department of Surgery

This fall, as we welcome new PGY1
residents and a host of new faculty
members, there is great excitement here
in the Department of Surgery.
On the clinical front, we have gained
additional work at the Methodist Hospital,
have grown the Heart Transplant and
Advanced Heart Failure Program, have seen
an upswing in liver transplants, and are now
the busiest hospital by surgical volume for
pancreas resections in the tri-state area!
On the quality front, Dr. Herbert Cohn and
Randi Altmark, RN, BSN, CNOR have done
a tremendous job with the National Surgical
Quality Improvement Program. Using those
data we have organized the Surgical Care
Committee and new Surgical Care Bundle
and are driving changes in practice, and
hopefully, better outcomes.
On the research front, our grant submissions
have doubled in the last three years.
Total grant awards for the last fiscal year
approached $2 million. We have completed
a large prospective randomized trial looking
at pancreaticojejunostomy following the
Whipple procedure, and have clinical trials
open in the Divisions of Vascular, Cardiac,
Transplant and General Surgery.
On the education front, Dr. Karen Chojnacki
has done a great job retooling our surgical
curriculum with the help of Drs. Niels
Martin and Vincent Armenti, and the
Chief Residents.
Finally, we thank Lara Allan Goldstein for her
work in greatly increasing the department’s
development dollars – most recently
accepting a generous gift from the Nicoletti
family to support an endowed professorship
in transplant surgery.
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Genetic Counselor Sarah Charles, MS, CGC of the Jefferson Kimmel Cancer Center Network
(JKCCN) educates families about their risk of developing an inherited disorder.

Jefferson Pancreas Tumor
Registry Opens for Enrollment
The Jefferson Pancreas Tumor Registry
(Jeff PTR) has been approved by the
Institutional Review Board of Thomas
Jefferson University Hospital and is
designed to help determine the links
between familial genetic variations,
environmental and occupational
influences, and the development of
pancreatic cancer
According to Principal Investigator,
Dr. Charles J. Yeo, “The purpose of the
Jeff PTR is to determine whether
pancreas cancer occurs more frequently
in families with a history of the disease,
and to determine the environmental and
occupational risk factors to which
pancreas cancer patients have been
exposed.” Participants will complete a

The goal is to diagnose
pancreatic cancer early when
it is easier to treat.
detailed questionnaire and may be asked
to submit a blood sample and/or cheek
swab. The questionnaire is designed to
elicit the family health history of a
patient with pancreas cancer or a nonaffected family member, and to
document exposure to occupational and
environmental factors, such as residential
radon, asbestos, and second-hand

tobacco smoke. The Jeff PTR is a
longitudinal study in which participants
may engage in long-term follow-up and
receive information regarding scientific
and epidemiological breakthroughs in
pancreas cancer.
Research has shown that certain rare
genetic conditions are associated with an
increased risk of pancreatic cancer,
including familial breast-ovarian cancer,
familial melanoma, familial colon cancer,
hereditary pancreatitis, and Peutz-Jegher’s

syndrome. Genetic Counselor Sarah
Charles, MS, CGC of the Jefferson
Kimmel Cancer Center Network
(JKCCN) educates families about their
risk of developing an inherited disorder.
Ms. Charles explains, “We haven’t yet
identified a causative gene to allow
predictive testing for pancreatic cancer.
But, for patients with a strong family
history of pancreatic cancer, we can offer
risk assessments and possibly surveillance
with endoscopic ultrasound.”
Such high risk patients may be
referred to Jefferson gastroenterologists
such as Thomas Kowalski, MD and
David Loren, MD to discuss the pros and
cons of invasive surveillence. The goal is
to diagnose pancreatic cancer early when
it is easier to treat. For persons who do
develop pancreatic cancer, Jefferson
physicians may use the results of genetic
testing to select the most effective
therapy. Targeted therapy for pancreas
cancer is becoming a reality in part due
to recent discoveries made in the
laboratory of Jonathan Brody, PhD,
Assistant Professor of Surgery, where
molecular studies have clearly indicated
survival advantages with the use of
targeted chemotherapy treatment.
For more information about the Jefferson
Pancreas Tumor Registry please visit
www.jeffersonhospital.org/pancreasregistry

Please Welcome

Meet Our
Surgical Interns
Jefferson surgeons are
currently assisted by
an exceptional group of
categorical interns, half of
them Jefferson Medical
College graduates. These
doctors, who recently
matched with Jefferson,
started on June 20, 2008 (l to r):
Danielle Pineda, MD, Jefferson Medical
College; Richard Burkhart, MD, Boston
University School of Medicine;
Aleksandra Policha, MD, SUNY/Syracuse;
Daniel Relles, MD, Jefferson Medical College;
Christina Khan, MD, PhD, University of Illinois;

and Jason Walls, MD, Jefferson
Medical College
We are also pleased to welcome back
two additional Jefferson Medical College
graduates, Carrie Houssock, MD, and Jordan
Goldhammer, MD, as preliminary interns in
General Surgery.
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